^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CNTY-101
i
Other names: CNTY-101, CD19 targeting iPSC-Derived CAR-NK cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Century Therap
Drug class:
CD19 inhibitor, NK cell stimulant, IL-15 stimulant
Related drugs:
6d
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (CALiPSO-1) (clinicaltrials.gov)
P1, N=48, Recruiting, Century Therapeutics, Inc. | N=30 --> 48
Enrollment change
|
IL2 (Interleukin 2)
|
CNTY-101
3ms
CALiPSO-1: A Study of CNTY-101 in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
P1, N=26, Recruiting, Century Therapeutics, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
IL2 (Interleukin 2)
|
CNTY-101
9ms
CALiPSO-1: A Study of CNTY-101 in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
P1, N=26, Not yet recruiting, Century Therapeutics, Inc.
New P1 trial
|
IL2 (Interleukin 2)
|
CNTY-101
1year
Multiple Doses of Cnty-101, an iPSC-Derived Allogeneic CD19 Targeting CAR-NK Product, Are Safe and Result in Tumor Microenvironment Changes Associated with Response: A Case Study (ASH 2023)
Cycles 1 and 2 included three days of standard Fludarabine and Cyclophosphamide lymphodepletion (LDC), cycles 3 and 4 were given with no LDC. The treatment was associated with changes in tumor microenvironment within 8 days post-infusion, augmentation of adaptive T cell responses, and tumor shrinkage. Updated data will be presented at the conference.
Clinical
|
EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • B2M (Beta-2-microglobulin) • IL2 (Interleukin 2) • HLA-E (Major Histocompatibility Complex, Class I, E) • IL15 (Interleukin 15)
|
CD19 positive
|
cyclophosphamide • fludarabine IV • CNTY-101
over1year
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies. (ASCO 2023)
In addition to safety and efficacy endpoints, the trial will evaluate exploratory PK, immunogenicity and pharmacodynamic endpoints including evaluations of tumor cfDNA, iNK tumor trafficking and serum cytokines. Clinical trial information: NCT05336409.
Clinical • P1 data
|
CD19 (CD19 Molecule) • IL2 (Interleukin 2)
|
CD19 positive • CD19 expression
|
CNTY-101
over1year
iPSC-derived CAR-NK cell therapy: nominating clinical candidate clones through integrated multi-functional analysis (AACR 2023)
CNTY-101 is an induced Pluripotent Stem Cell (iPSC) derived Chimeric Antigen Receptor (CAR) NK cell clinical candidate for the treatment of B-cell malignancies...In addition, we identify biomarkers measured during the differentiation process that are correlated with functional performance, such as the level of CD94 surface expression and tumor killing. Finally, we discuss the application of functional multi-omics to candidate clone nomination for Century Therapeutics’ pipeline of future products.
Clinical
|
EGFR (Epidermal growth factor receptor) • CD19 (CD19 Molecule) • B2M (Beta-2-microglobulin) • HLA-E (Major Histocompatibility Complex, Class I, E) • CIITA (Class II Major Histocompatibility Complex Transactivator) • IL15 (Interleukin 15)
|
CNTY-101
almost2years
ELiPSE-1: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (clinicaltrials.gov)
P1, N=75, Recruiting, Century Therapeutics, Inc. | Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2025 --> Aug 2025
Enrollment open • Trial primary completion date
|
CD19 (CD19 Molecule)
|
CD19 positive
|
CNTY-101
over2years
ELiPSE-1: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (clinicaltrials.gov)
P1, N=75, Not yet recruiting, Century Therapeutics, Inc.
New P1 trial
|
CD19 (CD19 Molecule)
|
CD19 positive
|
CNTY-101
Share via
